Helix BioPharma Corp. to Present at Rodman & Renshaw Annual Global Investment Conference
05 Settembre 2013 - 10:30PM
Marketwired
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a
biopharmaceutical company developing drug candidates for the
prevention and treatment of cancer, today announced that Mr. Robert
Verhagen, Chief Executive Officer of the Company, will be
presenting at the Rodman & Renshaw Global Investment Conference
on September 9, 2013.
The presentation will focus on the activities of Helix in the
area of cancer, including an overview of its lead candidates
L-DOS47, which is currently in a Phase I/II clinical trial for
non-small cell lung cancer, and Topical Interferon Alpha-2b, for
the treatment of cervical lesions due to HPV infection. The
presentation will be made available through Helix's website soon
after the conference.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Investor Relations: Helix BioPharma Corp. Tel: 905
841-2300 Email: ir@helixbiopharma.com
Grafico Azioni Helix BioPharma (TSX:HBP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Helix BioPharma (TSX:HBP)
Storico
Da Giu 2023 a Giu 2024